Cellectis Success With Off-The-Shelf CAR-T Threatens Kite, Juno, Novartis

An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite, Juno and Novartis, may become commercially obsolete before they even reach the market.